roid dose began to be tapered, and after 7 weeks, the dose could be tapered to half the maximum dose.
Efficacy and Safety of Chaperonin 10 in Patients With Moderate to Severe Plaque Psoriasis: Evidence of Utility Beyond a Single Indication
C haperonin 10 is a highly conserved protein that is essential in protein folding. Recombinant chaperonin 10 (Cpn10) (1 amino acid different to native chaperonin 10) and has immunomodulatory function in vitro and in vivo. 1, 2 Treatment with Cpn10 improved clinical disease activity in patients with rheumatoid arthritis and downregulated cytokine responses of immune cells to cellular stimuli. 2 An exploratory study of Cpn10 treatment for chronic plaque psoriasis is reported.
Methods. Forty patients were screened, and 24 (aged 18 to 75 years) with plaque psoriasis for at least 6 months prior to screening, 10% or greater of the body surface area affected by plaque psoriasis, a Psoriasis Area and Severity Index (PASI) score of 12 or higher (severe psoriasis), and a Physician's Global Assessment (PGA) score of at least moderate at screening despite current therapies were selected. Patients taking psoriasis medications were eligible if the regimen they had been following was a stable systemic dose for 28 days or longer prior to treatment with Cpn10 or 14 days or longer with topical dosing. Exclusion criteria were infections, malignant neoplasms, abnormal hematology, renal, or liver function test findings, and treatment with any anti-tumor necrosis factor ␣ (TNF-␣) agents or immunosuppressive drugs within 28 days of starting Cpn10 treatment. In this singlecenter, double-blind study, patients were randomized into 5-, 7.5-, and 10-mg treatment groups of Cpn10 (XToll; CBio Limited, Brisbane, Australia) that was given intravenously twice weekly for 12 weeks. Outcomes were PASI and PGA scores and the percentages of patients with at least a 50%, 75%, or 90% improvement in PASI scores (PASI 50, PASI 75, and PASI 90). In vitro peripheral blood mononuclear cell reactivity to lipopolysaccharide stimulation was measured by cytokine production. Safety was assessed by physical examination, adverse event profile, laboratory parameters, and vital signs. Table; Figure, C). A PASI 90 was observed in one patient in the 7.5-mg group on days 56 and 70 and in another patient in the 10-mg group on day 70. No difference was seen in between the dose groups at day 84 in the percentage of patients exhibiting a PASI 75 response (P=.08). Peripheral blood mononuclear cells isolated from patients after treatment with Cpn10 produced significantly less TNF-␣ (day 28, P=.046; day 56, P = .04) (baseline median, 1397 pg/mL) and interleukin 1␤ (day 28, P=.046; day 56, P=.03) (baseline median, 2567 pg/mL) in the 10-mg group (Figure, D) . The most common adverse event was exacerbation of psoriasis (4 cases during the study and 3 cases after the final dose). Decreased lymphocyte counts were observed in 6 patients, 2 of whom had upper respiratory tract infections. One patient was lymphopenic at screening, possibly associated with concomitant sarcoidosis. One patient with diabetes mellitus experienced loss of consciousness judged to be unrelated to the study drug. Three adverse events were rated as probably treatment related (scotoma, psoriasis flare, increased proteinuria). Four patients showed a 4-fold increase in antibody titer to Cpn10. The rel-
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evance for efficacy is unknown as clinical improvement in these patients was seen.
Comment. This exploratory study shows preliminary evidence of short-term efficacy and safety and decreased release of TNF-␣ and interleukin 1␤, which is noteworthy in inflammation. 3 Lack of placebo is an acknowledged limitation of this pilot study as marked placebo effects are observed in psoriasis studies. 4 Nevertheless, short-term Cpn10 treatment led to rapid reduction in disease parameters in accord with our earlier observations of disease-modifying activity in chronic inflammatory processes.
1,2 These results will guide the design of a definitive placebo-controlled study and they raise the possibility that Cpn10 may regulate inflammation in a range of therapeutic areas. 
